Bio-Techne (NASDAQ:TECH) Sets New 52-Week High – Here’s Why

Posted by Brian Himes on Aug 12th, 2026

Bio-Techne Corp (NASDAQ:TECH – Get Free Report) reached a new 52-week high on Monday . The stock traded as high as $72.37 and last traded at $72.2540, with a volume of 360 shares. The stock had previously closed at $72.29.

Analysts Set New Price Targets

A number of analysts have recently issued reports on TECH shares. Stifel Nicolaus set a $50.00 target price on Bio-Techne in a report on Thursday, May 7th. TD Cowen downgraded Bio-Techne from a “buy” rating to a “hold” rating and lifted their price target for the company from $65.00 to $73.00 in a report on Monday, June 29th. Zacks Research lowered Bio-Techne from a “hold” rating to a “strong sell” rating in a research report on Monday, June 8th. Piper Sandler started coverage on Bio-Techne in a research note on Thursday, June 11th. They issued a “neutral” rating and a $65.00 price objective for the company. Finally, Robert W. Baird raised their price objective on Bio-Techne from $49.00 to $73.00 and gave the stock a “neutral” rating in a research report on Friday, June 26th. Three research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Bio-Techne presently has an average rating of “Hold” and an average price target of $68.08.

View Our Latest Report on Bio-Techne

Bio-Techne Trading Up 0.0%

The stock has a market capitalization of $11.30 billion, a price-to-earnings ratio of 104.57, a price-to-earnings-growth ratio of 8.59 and a beta of 1.28. The company has a current ratio of 4.49, a quick ratio of 3.18 and a debt-to-equity ratio of 0.10. The company has a fifty day moving average of $66.18 and a two-hundred day moving average of $59.18.

Institutional Trading of Bio-Techne

Large investors have recently modified their holdings of the company. Goldman Sachs Group Inc. lifted its position in Bio-Techne by 12.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,063,939 shares of the biotechnology company’s stock worth $62,379,000 after acquiring an additional 113,634 shares during the last quarter. Woodline Partners LP increased its stake in shares of Bio-Techne by 40.0% in the first quarter. Woodline Partners LP now owns 13,356 shares of the biotechnology company’s stock worth $783,000 after purchasing an additional 3,814 shares during the period. EverSource Wealth Advisors LLC increased its stake in shares of Bio-Techne by 506.3% in the second quarter. EverSource Wealth Advisors LLC now owns 673 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 562 shares during the period. First Trust Advisors LP lifted its position in shares of Bio-Techne by 1,085.7% during the 2nd quarter. First Trust Advisors LP now owns 105,418 shares of the biotechnology company’s stock worth $5,424,000 after purchasing an additional 96,527 shares during the last quarter. Finally, Natixis lifted its position in shares of Bio-Techne by 82.6% during the 2nd quarter. Natixis now owns 24,991 shares of the biotechnology company’s stock worth $1,286,000 after purchasing an additional 11,306 shares during the last quarter. 98.95% of the stock is owned by institutional investors.

About Bio-Techne

(Get Free Report)

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.